Genotype and allele frequencies of polymorphic UGT1A9 in the Polish population

  • Oliwia Zakerska
  • Marzena Skrzypczak-Zielinska
  • Adam Mikstacki
  • Barbara Tamowicz
  • Bianka Malengowska
  • Marlena Szalata
  • Ryszard Slomski
Short Communication

Abstract

The human UDP-glucuronosyltransferase 1A9 (UGT1A9) plays a central role in the metabolism of different therapeutic drugs, carcinogens and endobiotics. The UGT1A9 gene shows genetic polymorphism with frequencies significantly different in populations and ethnic groups. Many of these genetic variants are directly responsible for polymorphic drug metabolism. Three crucial alleles of UGT1A9, UGT1A9*3 (p.Met33Thr), *4 (p.Tyr242X), *5 (p.Asp256Asn) are associated with decrease or absence of enzyme activity, which intensify the risk of toxic effect during biotransformation. The goal of the present study was to discover frequencies of these genetic variations in 308 healthy individuals representing Polish population. The genotypes were determined by pyrosequencing. We demonstrated that the frequency of the variant UGT1A9*3 was 0.016, which suggests the need for detailed analysis of its effect on important drugs metabolism level in Polish population. Alleles UGT1A9*4 and UGT1A9*5 were not present in any of the subjects. So far, no studies have been conducted in which the distribution of these alleles has been determined in the Polish population.

Keywords

UDP-glucuronosyltransferase UGT1A9 Polymorphic drug metabolism Polish population Allele frequencies 

Notes

Acknowledgments

This study was supported by grant from the Ministry of Science and Higher Education in Poland (grant number: N401 037 838), European Regional Development Fund—ERDF, European Fund for Innovative Economy and Foundation for Polish Science.

References

  1. Bernard O, Guillemette C (2004) The main role of UGT1A9 in the hepatic metabolism of mycophenolic acid and the effects of naturally occurring variants. Drug Metab Dispos 32:775–778PubMedCrossRefGoogle Scholar
  2. Girard H, Court MH, Bernard O, Fortier LC, Villeneuve L, Hao Q, Greenblatt DJ, von Moltke LL, Perussed L, Guillemette C (2004) Identification of common polymorphisms in the promoter of the UGT1A9 gene: evidence that UGT1A9 protein and activity levels are strongly genetically controlled in the liver. Pharmacogenetics 14(8):501–515PubMedCrossRefGoogle Scholar
  3. Girard H, Villeneuve L, Court MH, Fortier LC, Caron P, Hao Q, von Moltke LL, Greenblatt DJ, Guillemette C (2006) The novel UGT1A9 intronic I399 polymorphism appears as a predictor of 7-ethyl-10-hydroxycamptothecin glucuronidation levels in the liver. Drug Metab Dispos 34(7):1220–1228PubMedCrossRefGoogle Scholar
  4. Gong QH, Cho JW, Huang T, Potter C, Gholami N, Basu NK, Kubota S, Carvalho S, Pennington MW, Owens IS, Popescu NC (2001) Thirteen UDPglucuronosyltransferase genes are encoded at the human UGT1 gene complex locus. Pharmacogenetics 11(4):357–368PubMedCrossRefGoogle Scholar
  5. Jinno H, Saeki M, Saito Y, Tanaka-Kagawa T, Hanioka N, Sai K, Kaniwa N, Ando M, Shirao K, Minami H, Ohtsu A, Yoshida T, Saijo N, Ozawa S, Sawada J (2003) Functional characterization of human UDP-glucuronosyltransferase 1A9 variant, D256N, found in Japanese cancer patients. J Pharmacol Exp Ther 306(2):688–693PubMedCrossRefGoogle Scholar
  6. King CD, Rios GR, Green MD, Tephly TR (2000) UDP-glucuronosyltransferases. Curr Drug Metab 1(2):143–161 ReviewPubMedCrossRefGoogle Scholar
  7. Korprasertthaworn P, Udomuksorn W, Yoovathaworn K (2009) Three novel single nucleotide polymorphisms of UGT1A9 in a Thai population. Drug Metab Pharmacokinet 24(5):482–485PubMedCrossRefGoogle Scholar
  8. Lévesque E, Delage R, Benoit-Biancamano MO, Caron P, Bernard O, Couture F, Guillemette C (2007) The impact of UGT1A8, UGT1A9, and UGT2B7 genetic polymorphisms on the pharmacokinetic profile of mycophenolic acid after a single oral dose in healthy volunteers. Clin Pharmacol Ther 81(3):392–400PubMedCrossRefGoogle Scholar
  9. Mehlotra RK, Bockarie MJ, Zimmerman PA (2007) Prevalence of UGT1A9 and UGT2B7 nonsynonymous single nucleotide polymorphisms in West African, Papua New Guinean, and North American populations. Eur J Clin Pharmacol 63(1):1–8PubMedCrossRefGoogle Scholar
  10. Olson KC, Dellinger RW, Zhong Q, Sun D, Amin S, Spratt TE, Lazarus P (2009) Functional characterization of low-prevalence missense polymorphisms in the UDP-glucuronosyltransferase 1A9 gene. Drug Metab Dispos 37(10):1999–2007PubMedCrossRefGoogle Scholar
  11. Paoluzzi L, Singh AS, Price DK, Danesi R, Mathijssen RH, Verweij J et al (2004) Influence of genetic variants in UGT1A1 and UGT1A9 on the in vitro glucuronidation of SN-38. J Clin Pharmacol 44:854–860PubMedCrossRefGoogle Scholar
  12. Parke TJ, Stevens JE, Rice AS, Greenaway CL, Bray RJ, Smith PJ et al (1992) Metabolic acidosis and fatal myocardial failure after propofol infusion in children: five case reports. BMJ 305(6854):613–616PubMedCrossRefGoogle Scholar
  13. Piepoli A, Gentile A, Valvano MR, Barana D, Oliani C, Cotugno R, Quitadamo M, Andriulli A, Perri F (2006) Lack of association between UGT1A7, UGT1A9, ARP, SPINK1 and CFTR gene polymorphisms and pancreatic cancer in Italian patients. World J Gastroenterol 12(39):6343–6348PubMedGoogle Scholar
  14. Ritter JK, Chen F, Sheen YY, Tran HM, Kimura S, Yeatman MT, Owens IS (1992) A novel complex locus UGT1 encodes human bilirubin, phenol, and other UDP-glucuronosyltransferase isozymes with identical carboxyl termini. J Biol Chem 267(5):3257–3261PubMedGoogle Scholar
  15. Saeki M, Saito Y, Jinno H, Sai K, Komamura K, Ueno K, Kamakura S, Kitakaze M, Shirao K, Minami H, Ohtsu A, Yoshida T, Saijo N, Ozawa S, Sawada J (2003) Three novel single nucleotide polymorphisms in UGT1A9. Drug Metab Pharmacokinet 18(2):146–149PubMedCrossRefGoogle Scholar
  16. Saeki M, Saito Y, Jinno H, Sai K, Ozawa S et al (2006) Haplotype structures of the UGT1A gene complex in a Japanese population. Pharmacogenomics J 6(1):63–75PubMedCrossRefGoogle Scholar
  17. Strassburg CP, Manns MP, Tukey RH (1998) Expression of the UDP-glucuronosyltransferase 1A locus in human colon. Identification and characterization of the novel extrahepatic UGT1A8. J Biol Chem 273(15):8719–8726PubMedCrossRefGoogle Scholar
  18. Takahashi H, Maruo Y, Mori A, Iwai M, Sato H, Takeuchi Y (2008) Effect of D256 N and Y483D on propofol glucuronidation by human uridine 5′-diphosphate glucuronosyltransferase (UGT1A9). Basic Clin Pharmacol Toxicol 103(2):131–136PubMedCrossRefGoogle Scholar
  19. Thibaudeau J, Lépine J, Tojcic J, Duguay Y, Pelletier G, Plante M, Brisson J, Têtu B, Jacob S, Perusse L, Bélanger A, Guillemette C (2006) Characterization of common UGT1A8, UGT1A9, and UGT2B7 variants with different capacities to inactivate mutagenic 4-hydroxylated metabolites of estradiol and estrone. Cancer Res 66(1):125–133PubMedCrossRefGoogle Scholar
  20. Villeneuve L, Girard H, Fortier LC, Gagné JF, Guillemette C (2003) Novel functional polymorphisms in the UGT1A7 and UGT1A9 glucuronidating enzymes in Caucasian and African-American subjects and their impact on the metabolism of 7-ethyl-10-hydroxycamptothecin and flavopiridol anticancer drugs. J Pharmacol Exp Ther 307(1):117–128PubMedCrossRefGoogle Scholar
  21. Watanabe Y, Nakajima M, Yokoi T (2002) Troglitazone glucuronidation in human liver and intestine microsomes: high catalytic activity of UGT1A8 and UGT1A10. Drug Metab Dispos 30(12):1462–1469PubMedCrossRefGoogle Scholar
  22. Wolf AR, Potter F (2004) Propofol infusion in children: when does an anesthetic tool become an intensive care liability? Paediatr Anaesth 14:435–438PubMedCrossRefGoogle Scholar
  23. Yamanaka H, Nakajima M, Katoh M, Hara Y, Tachibana O, Yamashita J, McLeod HL, Yokoi T (2004) A novel polymorphism in the promoter region of human UGT1A9 gene (UGT1A9*22) and its effects on the transcriptional activity. Pharmacogenetics 14(5):329–332PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag France 2012

Authors and Affiliations

  • Oliwia Zakerska
    • 1
    • 4
  • Marzena Skrzypczak-Zielinska
    • 2
  • Adam Mikstacki
    • 3
  • Barbara Tamowicz
    • 3
  • Bianka Malengowska
    • 4
  • Marlena Szalata
    • 2
    • 4
  • Ryszard Slomski
    • 2
    • 4
  1. 1.The NanoBioMedical CentreAdam Mickiewicz UniversityPoznanPoland
  2. 2.Institute of Human GeneticsPolish Academy of SciencesPoznanPoland
  3. 3.Department of Anaesthesiology and Intensive Care MedicinePoznan University of Medical SciencesPoznanPoland
  4. 4.Department of Biochemistry and BiotechnologyUniversity of Life SciencesPoznanPoland

Personalised recommendations